Management of medullary thyroid cancer

Minerva Endocrinologica

Volumn 36, Issue 1, 2011, Pages 87-98

  Ball, D W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prognosis; Radiotherapy; Thyroid cancer, medullary

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 131; EVEROLIMUS; EXELIXIS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PAZOPANIB; PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN RET; RADIOPHARMACEUTICAL AGENT; RAF PROTEIN; SORAFENIB; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; XL 184;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; APOPTOSIS; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION BIOPSY; BONE METASTASIS; BONE PAIN; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL THERAPY; CERVICAL LYMPH NODE; CONSTIPATION; CONTRAST ENHANCEMENT; DECREASED APPETITE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; DISTANT METASTASIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; ECTOPIC CORTICOTROPIN PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL CANCER; FATIGUE; FLATULENCE; FLUSHING; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; INTRACELLULAR SIGNALING; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHADENOPATHY; LYMPHOCYTOPENIA; METASTASIS; MICROINJECTION; MOUTH PAIN; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NECK DISSECTION; NEUTROPENIA; NONHUMAN; PARANEOPLASTIC SYNDROME; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; QT PROLONGATION; REOPERATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THYROID CANCER; THYROID MEDULLARY CANCER; THYROID NODULE; THYROIDECTOMY; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GENETIC MARKERS; HUMANS; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 79960029995     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011;21:125-34.
2. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
3. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7. (Pubitemid 351398539)
4. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42. (Pubitemid 44665646)
5. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998;48:265-73.
6. Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 2008,95:586-91.
7. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-34. (Pubitemid 40586235)
8. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26:22-8. (Pubitemid 36918813)
9. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999;229:880-7; discussion 887-8.
10. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070-5. (Pubitemid 36549878)
11. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997;79:132-138. (Pubitemid 26425518)
12. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP et at. Survival from rare cancer in adults: a population-based study. Lancet Oncol 2006;7:132-40.
13. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007;92:4185-90. (Pubitemid 350074730)
14. Szavcsur P, Godény M, Bajzik G, Lengyel E, Repa I, Trón L et al. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol 2005;31:183-90. (Pubitemid 40214755)
15. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-84. (Pubitemid 41606528)
16. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
17. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007;67:6956-64.
18. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
19. Blaugrund JE, Johns MM Jr, Eby YJ, Ball DW, Baylin SB, Hruban RH et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994;3:1895-7. (Pubitemid 24310493)
20. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 1994;3:1259-62.
21. Schilling T, Bürck J, Sinn HP, Clemens A, Otto HF, Höppner W et al. Prognostic value of codon 918 (ATG->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001;95:62-6.
22. Kurzrock R, Sherman SI, Ball DW, Forastiere A, Cohen RB, Mehra R et al. Activity of XL184, an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011 [In press].
23. Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am 2009;89:1193-204.
24. Kebebew E, Clark OH. Medullary thyroid cancer. Curr Treat Options Oncol. 2000;1:359-367.
25. Dackiw AP. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am 2010;43:365-74.
26. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM et al. Medullary carcinoma. J Natl Compr Canc Netw 2010;8:512-30.
27. Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery 2006;139:28-32.
28. Brierley JD, Tsang RW. External radiation therapy of medullary thyroid cancer. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management. Totowa, NJ: Humana; 2006. p. 605-7.
29. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-10. (Pubitemid 26303135)
30. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH et al. Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era. Head Neck 2008;30:883-8. (Pubitemid 352008948)
31. Greenblatt DY, Chen H. Palliation of advanced thyroid malignancies. Surg Oncol 2007;16:237-47. (Pubitemid 350192233)
32. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010;28(Suppl);abstr 5503.
33. Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol 2010;28:e390-2.
34. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705-11. (Pubitemid 46622142)
35. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009;94:1493-9.
36. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2496-9. (Pubitemid 44024606)
37. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004;204:197-211.
38. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res 1991;51:1596-9.
39. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801.
40. Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004;96:1231-9. (Pubitemid 39232714)
41. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A et al. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. J Clin Endocrinol Metab 2000;85:3898-907.
42. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-76. (Pubitemid 30083066)
43. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010;20:863-71.
44. Joao Bugalho M, Madureira D, Espadinha C, Paula Font A, Sobrinho LG. Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma. Eur J Endocrinol 2008;159:167-9.
45. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82:3741-7. (Pubitemid 27509365)
46. Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Saï-Maurel C, Faivre-Chauvet A et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer 2010;116:1053-8.
47. Chigurupati S, Kulkarni T, Thomas S, Shah G. Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 2005;65:8519-29. (Pubitemid 41330621)
48. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
49. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71.
50. L Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30.
51. De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010;28(Suppl);abstr 5504.
52. Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009;21:1585-92.
53. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mácke HR et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007;13:6696-702.
54. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234-45. (Pubitemid 38594811)